Register Now

AI

Published on February 15th, 2019 | by Emergent Enterprise

0

AI Is Rapidly Augmenting Healthcare and Longevity

Emergent Insight:

AI in the healthcare industry is a stellar example of how technology takes tedious, exacting work done by humans and accelerates it hyper speed. As Peter H. Diamandis spells out at Singularity Hub the inclusion of machine learning is optimizing drug design and driving it to results in a fraction of the existing time. Some may lament the jobs lost in this innovation but the focus should be on the lives saved instead.

Original Article:

Image Credit: Zapp2Photo / Shutterstock.com

When it comes to the future of healthcare, perhaps the only technology more powerful than CRISPR is artificial intelligence.

Over the past five years, healthcare AI startups around the globe raised over $4.3 billion across 576 deals, topping all other industries in AI deal activity.

During this same period, the FDA has given 70 AI healthcare tools and devices ‘fast-tracked approval’ because of their ability to save both lives and money.

The pace of AI-augmented healthcare innovation is only accelerating.

In Part 3 of this blog series on longevity and vitality, I cover the different ways in which AI is augmenting our healthcare system, enabling us to live longer and healthier lives.

In this blog, I’ll expand on:

  1. Machine learning and drug design
  2. Artificial intelligence and big data in medicine
  3. Healthcare, AI & China

Let’s dive in.

Machine Learning in Drug Design

What if AI systems, specifically neural networks, could predict the design of novel molecules (i.e. medicines) capable of targeting and curing any disease?

Imagine leveraging cutting-edge artificial intelligence to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.

And what if these molecules, accurately engineered by AIs, always worked? Such a feat would revolutionize our $1.3 trillion global pharmaceutical industry, which currently holds a dismal record of 1 in 10 target drugs ever reaching human trials.

It’s no wonder that drug development is massively expensive and slow. It takes over 10 years to bring a new drug to market, with costs ranging from $2.5 billion to $12 billion.

This inefficient, slow-to-innovate, and risk-averse industry is a sitting duck for disruption in the years ahead.

One of the hottest startups in digital drug discovery today is Insilico Medicine. Leveraging AI in its end-to-end drug discovery pipeline, Insilico Medicine aims to extend healthy longevity through drug discovery and aging research.

To continue reading, go here…

Tags: , ,


About the Author

Emergent Enterprise

The Emergent Enterprise (EE) website brings together current and important news in enterprise mobility and the latest in innovative technologies in the business world. The articles are hand selected by Emergent Enterprise and not the result of automated electronic aggregating. The site is designed to be a one-stop shop for anyone who has an ongoing interest in how technology is changing how the world does business and how it affects the workforce from the shop floor to the top floor. EE encourages visitor contributions and participation through comments, social media activity and ratings.



Back to Top ↑